Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777296 | 0.92 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL6778080 | 0.86 | CRHR1 (0.61) | CRHR1 | |
| SCHEMBL6778921 | 0.86 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL6779041 | 0.84 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL6775219 | 0.81 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL7220676 | 0.72 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7046432 | 0.72 | TYMS (0.48) | — | |
| SCHEMBL6776302 | 0.67 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL6352093 | 0.65 | CRHR1 (0.64) | CRHR1 | |
| SCHEMBL26534113 | 0.65 | NPY5R (0.47) | CRHR1MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630476-B2 | For therapy of anxiety, depression, and other psychiatric, neurological disorders, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-07 | — | — | US | claimed |
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-21 | — | — | US | claimed |
| US-6734185-B2 | Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-05-11 | — | — | US | disclosed |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| US-6630476-B2 | For therapy of anxiety, depression, and other psychiatric, neurological disorders, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885MAP2K7 1939/4885 |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885MAP2K7 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.